Troy Duster1. Show Affiliations » 1. New York University, New York, NY 10003, USA. troy.duster@nyu.edu
Abstract
Mesh: See more » African Americans/geneticsAge DistributionAgedAntineoplastic Agents/therapeutic useClinical Trials as TopicDrug ApprovalDrug CombinationsGefitinibHeart Failure/drug therapyHeart Failure/geneticsHeart Failure/mortalityHumansHydralazine/therapeutic useIsosorbide Dinitrate/therapeutic useLung Neoplasms/drug therapyMiddle AgedPatents as Topic/legislation & jurisprudenceQuinazolines/therapeutic useUnited StatesUnited States Food and Drug Administration
Substances: See more » Antineoplastic AgentsDrug CombinationsQuinazolinesisosorbide-hydralazine combinationHydralazineIsosorbide DinitrateGefitinib
Year: 2007 PMID: 17321318 DOI: 10.1016/S0140-6736(07)60320-1
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321